Follow The Filings

RAPP Rapport Therapeutics

Rapport Therapeutics earnings company data as of 3:59 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by RAPP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RAPP insider trades
  • $1.6M bought by 5 insiders
  • None no sales outside a trading plan
  • $46.8M sold by 5 insiders under 10b5-1 plans
  1. Paul M Silva Director
    Buy
    $100K 3,680 shares at $27.08 New stake
    Traded Oct 22 Filed Oct 22
    ↗
  2. Wendy B. Young Director
    Buy
    $100K 3,789 shares at $26.39 +40% to stake
    Traded Oct 22 Filed Oct 22
    ↗
  3. Steven M Paul Director
    Buy
    $974K 35,714 shares at $27.28 +86% to stake
    Traded Oct 22 Filed Oct 22
    ↗
  4. John Maraganore Director
    Buy
    $249K 9,411 shares at $26.45 New stake
    Traded Oct 22 Filed Oct 22
    ↗
  5. Troy A. Ignelzi CFO
    Buy
    $144K 5,500 shares at $26.10 +55% to stake
    Traded Oct 21 Filed Oct 21
    ↗
  6. Abraham Ceesay CEO
    Planned sale
    $143K 4,522 shares at $31.68 1% of stake
    Traded Oct 6–7 Filed Oct 8
    ↗
  7. Cheryl Gault COO
    Planned sale
    $332K 10,000 shares at $33.19 6.7% of stake
    Traded Sep 30 Filed Oct 1
    ↗
  8. Abraham Ceesay CEO
    Planned sale
    $87K 2,210 shares at $39.17 0.5% of stake
    Traded Sep 23 Filed Sep 24
    ↗
  9. Abraham Ceesay CEO
    Planned sale
    $374K 8,210 shares at $45.61 1.8% of stake
    Traded Sep 8 Filed Sep 9
    ↗
  10. Abraham Ceesay CEO
    Planned sale
    $938K 18,921 shares at $49.57 3.9% of stake
    Traded Aug 25 Filed Aug 26
    ↗
  11. Krishnaswamy Yeleswaram Chief Development Officer
    Planned sale
    $2.5M 50,160 shares at $50.47 20% of stake
    Traded Aug 24–25 Filed Aug 26
    ↗
  12. Krishnaswamy Yeleswaram Chief Development Officer
    Planned sale
    $20K 404 shares at $49.90 0.2% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  13. Abraham Ceesay CEO
    Planned sale
    $2.4M 51,499 shares at $47.25 9.6% of stake
    Traded Aug 10–11 Filed Aug 12
    ↗
  14. Abraham Ceesay CEO
    Planned sale
    $93K 2,210 shares at $42.11 0.4% of stake
    Traded Jul 27 Filed Jul 29
    ↗
  15. Abraham Ceesay CEO
    Planned sale
    $328K 8,210 shares at $40.00 1.5% of stake
    Traded Jul 14 Filed Jul 15
    ↗

Also filed in the last 12 months, not counted as buying or selling: 3 sales to cover taxes, 2 stock grants, and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated less than a minute ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.